June 3, 2017 The introduction of PARP inhibitors revolutionized the treatment of ovarian cancer, providing much-needed therapeutic options. However, clinical challenges remain as many patients are not candidates for PARP inhibitors and responses are often short-lived. Furthermore, biomarkers have not been established to definitively match patients with the most appropriate therapies. Despite these challenges,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.